Evidence map›Paper›PMID 39616213›Full record

ArticleCommunications medicine2024

Features of chronic urticaria after COVID-19 mRNA vaccine over time.

Johan Schwab, Mathilde Foglierini, Eva Pescosolido, Ines Pacheco, Gustavo A Ruiz Buendía, Natacha Madelon, Celine Pellaton, Véronique Banderet, Camillo Ribi, Marcel M Bergmann and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Johan SchwabDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Mathilde FoglieriniDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-7538-4262
Eva PescosolidoCentro Pediatrico del Mendrisiotto, Mendrisio, Switzerland.
Ines PachecoDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0009-0005-4720-9658
Gustavo A Ruiz BuendíaCentre of Vaccinology, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-4935-1480
Natacha MadelonCentre of Vaccinology, University of Geneva, Geneva, Switzerland.
Celine PellatonDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Véronique BanderetDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Camillo RibiDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Marcel M BergmannCentro Pediatrico del Mendrisiotto, Mendrisio, Switzerland.
Arnaud M DidierlaurentCentre of Vaccinology, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-4736-9003
Craig FenwickDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9435-0110
Olivier DuperrexCenter for Primary Care and Public Health (Unisanté) and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-0932-6846
Yannick D MullerDivision of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. Yannick.muller@chuv.ch.ORCID http://orcid.org/0000-0003-0513-7156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew onsets of chronic urticaria (CU) have been reported after repeated immunizations, mainly with the Moderna mRNA-1273 vaccine (Spikevax). This study aims to evaluate patients with CU after COVID-19 mRNA vaccination. The contribution of SARS-Cov2 infection, atopy and IgE against the vaccine was analyzed.

methodsWe monitored the features of patients who developed CU after vaccination through two surveys conducted in 2022 and 2023. Fifty individuals with CU underwent blood tests, and their results were compared with individuals without a history of urticaria (N = 135). The presence of anti-vaccine IgE was tested in 185 individuals with basophil activation tests (BAT). We assessed anti-SARS-Cov2 humoral response, and the presence of IgEs against common respiratory allergens (Phadiatop) as a surrogate for atopy.

resultsPost-vaccination CU occurs after a median interval of 10 days and significantly more after the Spikevax booster, affecting middle-aged individuals (median 41, 66% females). In 2023, CU was still active in 53% of the cases. Inducible forms of CU, primarily dermographism, are reported in 54% (2022) and 61% (2023) of the cases. BAT positivity is not specific to CU, anti-nucleocapsid positivity, or atopy but is significantly associated with higher anti-spike neutralizing activities and younger age. Four CU patients tolerate an additional dose of mRNA vaccine with no disease exacerbation/recurrence.

conclusionsThe spikevax booster induces anti-vaccine IgE independently of CU, the latter being not directly associated with COVID-19 infection nor atopy. The tolerance to a new booster in 4/4 patients suggests that the Spikevax vaccine indirectly triggers CU in predisposed individuals.

Identifiers

PMID39616213
PMCPMC11608360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.